nodes	percent_of_prediction	percent_of_DWPC	metapath
Dicyclomine—Neurological symptom—Cisplatin—bone cancer	0.0449	0.0449	CcSEcCtD
Dicyclomine—Tachyarrhythmia—Epirubicin—bone cancer	0.0381	0.0381	CcSEcCtD
Dicyclomine—Tachyarrhythmia—Doxorubicin—bone cancer	0.0353	0.0353	CcSEcCtD
Dicyclomine—Speech impairment NOS—Methotrexate—bone cancer	0.0341	0.0341	CcSEcCtD
Dicyclomine—Drug hypersensitivity—Epirubicin—bone cancer	0.0173	0.0173	CcSEcCtD
Dicyclomine—Necrosis—Cisplatin—bone cancer	0.0173	0.0173	CcSEcCtD
Dicyclomine—Ageusia—Cisplatin—bone cancer	0.0167	0.0167	CcSEcCtD
Dicyclomine—Drug hypersensitivity—Doxorubicin—bone cancer	0.016	0.016	CcSEcCtD
Dicyclomine—Pain—Carboplatin—bone cancer	0.0141	0.0141	CcSEcCtD
Dicyclomine—Nasal congestion—Cisplatin—bone cancer	0.0108	0.0108	CcSEcCtD
Dicyclomine—Paralysis—Methotrexate—bone cancer	0.0107	0.0107	CcSEcCtD
Dicyclomine—Amnesia—Cisplatin—bone cancer	0.0105	0.0105	CcSEcCtD
Dicyclomine—Paralysis—Epirubicin—bone cancer	0.01	0.01	CcSEcCtD
Dicyclomine—Thrombosis—Epirubicin—bone cancer	0.00983	0.00983	CcSEcCtD
Dicyclomine—Face oedema—Cisplatin—bone cancer	0.0095	0.0095	CcSEcCtD
Dicyclomine—Necrosis—Methotrexate—bone cancer	0.00948	0.00948	CcSEcCtD
Dicyclomine—Dermatitis atopic—Epirubicin—bone cancer	0.0094	0.0094	CcSEcCtD
Dicyclomine—Paralysis—Doxorubicin—bone cancer	0.00927	0.00927	CcSEcCtD
Dicyclomine—Thrombosis—Doxorubicin—bone cancer	0.0091	0.0091	CcSEcCtD
Dicyclomine—Breast disorder—Cisplatin—bone cancer	0.00889	0.00889	CcSEcCtD
Dicyclomine—Necrosis—Epirubicin—bone cancer	0.00887	0.00887	CcSEcCtD
Dicyclomine—Apnoea—Methotrexate—bone cancer	0.00877	0.00877	CcSEcCtD
Dicyclomine—Dermatitis atopic—Doxorubicin—bone cancer	0.0087	0.0087	CcSEcCtD
Dicyclomine—Speech disorder—Methotrexate—bone cancer	0.00865	0.00865	CcSEcCtD
Dicyclomine—Ageusia—Epirubicin—bone cancer	0.00859	0.00859	CcSEcCtD
Dicyclomine—Necrosis—Doxorubicin—bone cancer	0.00821	0.00821	CcSEcCtD
Dicyclomine—Delirium—Epirubicin—bone cancer	0.00809	0.00809	CcSEcCtD
Dicyclomine—Ageusia—Doxorubicin—bone cancer	0.00795	0.00795	CcSEcCtD
Dicyclomine—Delirium—Doxorubicin—bone cancer	0.00749	0.00749	CcSEcCtD
Dicyclomine—Dyskinesia—Epirubicin—bone cancer	0.00741	0.00741	CcSEcCtD
Dicyclomine—Injection site reaction—Epirubicin—bone cancer	0.00692	0.00692	CcSEcCtD
Dicyclomine—Dyskinesia—Doxorubicin—bone cancer	0.00685	0.00685	CcSEcCtD
Dicyclomine—Injection site reaction—Doxorubicin—bone cancer	0.0064	0.0064	CcSEcCtD
Dicyclomine—Eye disorder—Cisplatin—bone cancer	0.00636	0.00636	CcSEcCtD
Dicyclomine—Cardiac disorder—Cisplatin—bone cancer	0.00632	0.00632	CcSEcCtD
Dicyclomine—Thrombophlebitis—Methotrexate—bone cancer	0.00624	0.00624	CcSEcCtD
Dicyclomine—Immune system disorder—Cisplatin—bone cancer	0.00615	0.00615	CcSEcCtD
Dicyclomine—Mediastinal disorder—Cisplatin—bone cancer	0.00613	0.00613	CcSEcCtD
Dicyclomine—Erythema—Cisplatin—bone cancer	0.00593	0.00593	CcSEcCtD
Dicyclomine—Thrombophlebitis—Epirubicin—bone cancer	0.00584	0.00584	CcSEcCtD
Dicyclomine—Vision blurred—Cisplatin—bone cancer	0.00558	0.00558	CcSEcCtD
Dicyclomine—Lethargy—Methotrexate—bone cancer	0.00551	0.00551	CcSEcCtD
Dicyclomine—Ill-defined disorder—Cisplatin—bone cancer	0.0055	0.0055	CcSEcCtD
Dicyclomine—Thrombophlebitis—Doxorubicin—bone cancer	0.0054	0.0054	CcSEcCtD
Dicyclomine—Malaise—Cisplatin—bone cancer	0.00534	0.00534	CcSEcCtD
Dicyclomine—Lethargy—Epirubicin—bone cancer	0.00516	0.00516	CcSEcCtD
Dicyclomine—Mood swings—Methotrexate—bone cancer	0.00511	0.00511	CcSEcCtD
Dicyclomine—Diplopia—Epirubicin—bone cancer	0.00505	0.00505	CcSEcCtD
Dicyclomine—Discomfort—Cisplatin—bone cancer	0.00498	0.00498	CcSEcCtD
Dicyclomine—Affect lability—Epirubicin—bone cancer	0.00497	0.00497	CcSEcCtD
Dicyclomine—Breast disorder—Methotrexate—bone cancer	0.00488	0.00488	CcSEcCtD
Dicyclomine—Face oedema—Epirubicin—bone cancer	0.00488	0.00488	CcSEcCtD
Dicyclomine—Anaphylactic shock—Cisplatin—bone cancer	0.00484	0.00484	CcSEcCtD
Dicyclomine—Oedema—Cisplatin—bone cancer	0.00484	0.00484	CcSEcCtD
Dicyclomine—Mood swings—Epirubicin—bone cancer	0.00479	0.00479	CcSEcCtD
Dicyclomine—Lethargy—Doxorubicin—bone cancer	0.00477	0.00477	CcSEcCtD
Dicyclomine—Nervous system disorder—Cisplatin—bone cancer	0.00474	0.00474	CcSEcCtD
Dicyclomine—Tachycardia—Cisplatin—bone cancer	0.00472	0.00472	CcSEcCtD
Dicyclomine—Diplopia—Doxorubicin—bone cancer	0.00468	0.00468	CcSEcCtD
Dicyclomine—Anorexia—Cisplatin—bone cancer	0.00461	0.00461	CcSEcCtD
Dicyclomine—Affect lability—Doxorubicin—bone cancer	0.0046	0.0046	CcSEcCtD
Dicyclomine—Breast disorder—Epirubicin—bone cancer	0.00457	0.00457	CcSEcCtD
Dicyclomine—Face oedema—Doxorubicin—bone cancer	0.00451	0.00451	CcSEcCtD
Dicyclomine—Muscular weakness—Epirubicin—bone cancer	0.00446	0.00446	CcSEcCtD
Dicyclomine—Mood swings—Doxorubicin—bone cancer	0.00443	0.00443	CcSEcCtD
Dicyclomine—Abdominal distension—Epirubicin—bone cancer	0.0044	0.0044	CcSEcCtD
Dicyclomine—Paraesthesia—Cisplatin—bone cancer	0.00434	0.00434	CcSEcCtD
Dicyclomine—Dyspnoea—Cisplatin—bone cancer	0.00431	0.00431	CcSEcCtD
Dicyclomine—Erectile dysfunction—Methotrexate—bone cancer	0.0043	0.0043	CcSEcCtD
Dicyclomine—Breast disorder—Doxorubicin—bone cancer	0.00422	0.00422	CcSEcCtD
Dicyclomine—Decreased appetite—Cisplatin—bone cancer	0.0042	0.0042	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Cisplatin—bone cancer	0.00417	0.00417	CcSEcCtD
Dicyclomine—Drowsiness—Methotrexate—bone cancer	0.00416	0.00416	CcSEcCtD
Dicyclomine—Pain—Cisplatin—bone cancer	0.00414	0.00414	CcSEcCtD
Dicyclomine—Muscular weakness—Doxorubicin—bone cancer	0.00412	0.00412	CcSEcCtD
Dicyclomine—Abdominal distension—Doxorubicin—bone cancer	0.00407	0.00407	CcSEcCtD
Dicyclomine—Feeling abnormal—Cisplatin—bone cancer	0.00398	0.00398	CcSEcCtD
Dicyclomine—Drowsiness—Epirubicin—bone cancer	0.00389	0.00389	CcSEcCtD
Dicyclomine—Drowsiness—Doxorubicin—bone cancer	0.0036	0.0036	CcSEcCtD
Dicyclomine—Hypersensitivity—Cisplatin—bone cancer	0.00356	0.00356	CcSEcCtD
Dicyclomine—Eye disorder—Methotrexate—bone cancer	0.00349	0.00349	CcSEcCtD
Dicyclomine—Hypoaesthesia—Epirubicin—bone cancer	0.00348	0.00348	CcSEcCtD
Dicyclomine—Asthenia—Cisplatin—bone cancer	0.00347	0.00347	CcSEcCtD
Dicyclomine—Cardiac disorder—Methotrexate—bone cancer	0.00347	0.00347	CcSEcCtD
Dicyclomine—Immune system disorder—Methotrexate—bone cancer	0.00337	0.00337	CcSEcCtD
Dicyclomine—Mediastinal disorder—Methotrexate—bone cancer	0.00337	0.00337	CcSEcCtD
Dicyclomine—Mental disorder—Methotrexate—bone cancer	0.00327	0.00327	CcSEcCtD
Dicyclomine—Eye disorder—Epirubicin—bone cancer	0.00327	0.00327	CcSEcCtD
Dicyclomine—Erythema—Methotrexate—bone cancer	0.00325	0.00325	CcSEcCtD
Dicyclomine—Cardiac disorder—Epirubicin—bone cancer	0.00324	0.00324	CcSEcCtD
Dicyclomine—Hypoaesthesia—Doxorubicin—bone cancer	0.00322	0.00322	CcSEcCtD
Dicyclomine—Immune system disorder—Epirubicin—bone cancer	0.00316	0.00316	CcSEcCtD
Dicyclomine—Mediastinal disorder—Epirubicin—bone cancer	0.00315	0.00315	CcSEcCtD
Dicyclomine—Vomiting—Cisplatin—bone cancer	0.00307	0.00307	CcSEcCtD
Dicyclomine—Vision blurred—Methotrexate—bone cancer	0.00306	0.00306	CcSEcCtD
Dicyclomine—Mental disorder—Epirubicin—bone cancer	0.00306	0.00306	CcSEcCtD
Dicyclomine—Rash—Cisplatin—bone cancer	0.00305	0.00305	CcSEcCtD
Dicyclomine—Dermatitis—Cisplatin—bone cancer	0.00305	0.00305	CcSEcCtD
Dicyclomine—Erythema—Epirubicin—bone cancer	0.00304	0.00304	CcSEcCtD
Dicyclomine—Eye disorder—Doxorubicin—bone cancer	0.00302	0.00302	CcSEcCtD
Dicyclomine—Ill-defined disorder—Methotrexate—bone cancer	0.00302	0.00302	CcSEcCtD
Dicyclomine—Cardiac disorder—Doxorubicin—bone cancer	0.003	0.003	CcSEcCtD
Dicyclomine—Tension—Epirubicin—bone cancer	0.00299	0.00299	CcSEcCtD
Dicyclomine—Nervousness—Epirubicin—bone cancer	0.00296	0.00296	CcSEcCtD
Dicyclomine—Malaise—Methotrexate—bone cancer	0.00293	0.00293	CcSEcCtD
Dicyclomine—Immune system disorder—Doxorubicin—bone cancer	0.00292	0.00292	CcSEcCtD
Dicyclomine—Mediastinal disorder—Doxorubicin—bone cancer	0.00291	0.00291	CcSEcCtD
Dicyclomine—Nausea—Cisplatin—bone cancer	0.00287	0.00287	CcSEcCtD
Dicyclomine—Vision blurred—Epirubicin—bone cancer	0.00287	0.00287	CcSEcCtD
Dicyclomine—Mental disorder—Doxorubicin—bone cancer	0.00283	0.00283	CcSEcCtD
Dicyclomine—Ill-defined disorder—Epirubicin—bone cancer	0.00282	0.00282	CcSEcCtD
Dicyclomine—Erythema—Doxorubicin—bone cancer	0.00282	0.00282	CcSEcCtD
Dicyclomine—Agitation—Epirubicin—bone cancer	0.0028	0.0028	CcSEcCtD
Dicyclomine—Tension—Doxorubicin—bone cancer	0.00276	0.00276	CcSEcCtD
Dicyclomine—Malaise—Epirubicin—bone cancer	0.00274	0.00274	CcSEcCtD
Dicyclomine—Discomfort—Methotrexate—bone cancer	0.00273	0.00273	CcSEcCtD
Dicyclomine—Nervousness—Doxorubicin—bone cancer	0.00273	0.00273	CcSEcCtD
Dicyclomine—Syncope—Epirubicin—bone cancer	0.00273	0.00273	CcSEcCtD
Dicyclomine—Palpitations—Epirubicin—bone cancer	0.00269	0.00269	CcSEcCtD
Dicyclomine—Confusional state—Methotrexate—bone cancer	0.00268	0.00268	CcSEcCtD
Dicyclomine—Loss of consciousness—Epirubicin—bone cancer	0.00267	0.00267	CcSEcCtD
Dicyclomine—Anaphylactic shock—Methotrexate—bone cancer	0.00265	0.00265	CcSEcCtD
Dicyclomine—Vision blurred—Doxorubicin—bone cancer	0.00265	0.00265	CcSEcCtD
Dicyclomine—Hypertension—Epirubicin—bone cancer	0.00263	0.00263	CcSEcCtD
Dicyclomine—Ill-defined disorder—Doxorubicin—bone cancer	0.00261	0.00261	CcSEcCtD
Dicyclomine—Nervous system disorder—Methotrexate—bone cancer	0.0026	0.0026	CcSEcCtD
Dicyclomine—Agitation—Doxorubicin—bone cancer	0.00259	0.00259	CcSEcCtD
Dicyclomine—Discomfort—Epirubicin—bone cancer	0.00256	0.00256	CcSEcCtD
Dicyclomine—Malaise—Doxorubicin—bone cancer	0.00254	0.00254	CcSEcCtD
Dicyclomine—Dry mouth—Epirubicin—bone cancer	0.00253	0.00253	CcSEcCtD
Dicyclomine—Anorexia—Methotrexate—bone cancer	0.00253	0.00253	CcSEcCtD
Dicyclomine—Syncope—Doxorubicin—bone cancer	0.00252	0.00252	CcSEcCtD
Dicyclomine—Confusional state—Epirubicin—bone cancer	0.0025	0.0025	CcSEcCtD
Dicyclomine—Palpitations—Doxorubicin—bone cancer	0.00249	0.00249	CcSEcCtD
Dicyclomine—Oedema—Epirubicin—bone cancer	0.00248	0.00248	CcSEcCtD
Dicyclomine—Anaphylactic shock—Epirubicin—bone cancer	0.00248	0.00248	CcSEcCtD
Dicyclomine—Loss of consciousness—Doxorubicin—bone cancer	0.00247	0.00247	CcSEcCtD
Dicyclomine—Shock—Epirubicin—bone cancer	0.00244	0.00244	CcSEcCtD
Dicyclomine—Nervous system disorder—Epirubicin—bone cancer	0.00244	0.00244	CcSEcCtD
Dicyclomine—Hypertension—Doxorubicin—bone cancer	0.00243	0.00243	CcSEcCtD
Dicyclomine—Tachycardia—Epirubicin—bone cancer	0.00242	0.00242	CcSEcCtD
Dicyclomine—Insomnia—Methotrexate—bone cancer	0.0024	0.0024	CcSEcCtD
Dicyclomine—Paraesthesia—Methotrexate—bone cancer	0.00238	0.00238	CcSEcCtD
Dicyclomine—Discomfort—Doxorubicin—bone cancer	0.00237	0.00237	CcSEcCtD
Dicyclomine—Anorexia—Epirubicin—bone cancer	0.00237	0.00237	CcSEcCtD
Dicyclomine—Dyspnoea—Methotrexate—bone cancer	0.00237	0.00237	CcSEcCtD
Dicyclomine—Somnolence—Methotrexate—bone cancer	0.00236	0.00236	CcSEcCtD
Dicyclomine—Dry mouth—Doxorubicin—bone cancer	0.00234	0.00234	CcSEcCtD
Dicyclomine—Dyspepsia—Methotrexate—bone cancer	0.00234	0.00234	CcSEcCtD
Dicyclomine—Confusional state—Doxorubicin—bone cancer	0.00232	0.00232	CcSEcCtD
Dicyclomine—Decreased appetite—Methotrexate—bone cancer	0.00231	0.00231	CcSEcCtD
Dicyclomine—Anaphylactic shock—Doxorubicin—bone cancer	0.0023	0.0023	CcSEcCtD
Dicyclomine—Oedema—Doxorubicin—bone cancer	0.0023	0.0023	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Methotrexate—bone cancer	0.00229	0.00229	CcSEcCtD
Dicyclomine—Fatigue—Methotrexate—bone cancer	0.00229	0.00229	CcSEcCtD
Dicyclomine—Pain—Methotrexate—bone cancer	0.00227	0.00227	CcSEcCtD
Dicyclomine—Shock—Doxorubicin—bone cancer	0.00226	0.00226	CcSEcCtD
Dicyclomine—Nervous system disorder—Doxorubicin—bone cancer	0.00225	0.00225	CcSEcCtD
Dicyclomine—Insomnia—Epirubicin—bone cancer	0.00225	0.00225	CcSEcCtD
Dicyclomine—Tachycardia—Doxorubicin—bone cancer	0.00224	0.00224	CcSEcCtD
Dicyclomine—Paraesthesia—Epirubicin—bone cancer	0.00223	0.00223	CcSEcCtD
Dicyclomine—Dyspnoea—Epirubicin—bone cancer	0.00221	0.00221	CcSEcCtD
Dicyclomine—Somnolence—Epirubicin—bone cancer	0.00221	0.00221	CcSEcCtD
Dicyclomine—Anorexia—Doxorubicin—bone cancer	0.00219	0.00219	CcSEcCtD
Dicyclomine—Feeling abnormal—Methotrexate—bone cancer	0.00219	0.00219	CcSEcCtD
Dicyclomine—Dyspepsia—Epirubicin—bone cancer	0.00219	0.00219	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Methotrexate—bone cancer	0.00217	0.00217	CcSEcCtD
Dicyclomine—Decreased appetite—Epirubicin—bone cancer	0.00216	0.00216	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Epirubicin—bone cancer	0.00214	0.00214	CcSEcCtD
Dicyclomine—Fatigue—Epirubicin—bone cancer	0.00214	0.00214	CcSEcCtD
Dicyclomine—Pain—Epirubicin—bone cancer	0.00212	0.00212	CcSEcCtD
Dicyclomine—Constipation—Epirubicin—bone cancer	0.00212	0.00212	CcSEcCtD
Dicyclomine—Urticaria—Methotrexate—bone cancer	0.00211	0.00211	CcSEcCtD
Dicyclomine—Abdominal pain—Methotrexate—bone cancer	0.0021	0.0021	CcSEcCtD
Dicyclomine—Insomnia—Doxorubicin—bone cancer	0.00208	0.00208	CcSEcCtD
Dicyclomine—Paraesthesia—Doxorubicin—bone cancer	0.00206	0.00206	CcSEcCtD
Dicyclomine—Dyspnoea—Doxorubicin—bone cancer	0.00205	0.00205	CcSEcCtD
Dicyclomine—Feeling abnormal—Epirubicin—bone cancer	0.00205	0.00205	CcSEcCtD
Dicyclomine—Somnolence—Doxorubicin—bone cancer	0.00204	0.00204	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Epirubicin—bone cancer	0.00203	0.00203	CcSEcCtD
Dicyclomine—Dyspepsia—Doxorubicin—bone cancer	0.00202	0.00202	CcSEcCtD
Dicyclomine—Decreased appetite—Doxorubicin—bone cancer	0.002	0.002	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00198	0.00198	CcSEcCtD
Dicyclomine—Fatigue—Doxorubicin—bone cancer	0.00198	0.00198	CcSEcCtD
Dicyclomine—Urticaria—Epirubicin—bone cancer	0.00197	0.00197	CcSEcCtD
Dicyclomine—Constipation—Doxorubicin—bone cancer	0.00196	0.00196	CcSEcCtD
Dicyclomine—Pain—Doxorubicin—bone cancer	0.00196	0.00196	CcSEcCtD
Dicyclomine—Abdominal pain—Epirubicin—bone cancer	0.00196	0.00196	CcSEcCtD
Dicyclomine—Hypersensitivity—Methotrexate—bone cancer	0.00196	0.00196	CcSEcCtD
Dicyclomine—Asthenia—Methotrexate—bone cancer	0.0019	0.0019	CcSEcCtD
Dicyclomine—Feeling abnormal—Doxorubicin—bone cancer	0.00189	0.00189	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Doxorubicin—bone cancer	0.00188	0.00188	CcSEcCtD
Dicyclomine—Pruritus—Methotrexate—bone cancer	0.00188	0.00188	CcSEcCtD
Dicyclomine—Hypersensitivity—Epirubicin—bone cancer	0.00183	0.00183	CcSEcCtD
Dicyclomine—Urticaria—Doxorubicin—bone cancer	0.00183	0.00183	CcSEcCtD
Dicyclomine—Abdominal pain—Doxorubicin—bone cancer	0.00182	0.00182	CcSEcCtD
Dicyclomine—Asthenia—Epirubicin—bone cancer	0.00178	0.00178	CcSEcCtD
Dicyclomine—Pruritus—Epirubicin—bone cancer	0.00176	0.00176	CcSEcCtD
Dicyclomine—Dizziness—Methotrexate—bone cancer	0.00175	0.00175	CcSEcCtD
Dicyclomine—Hypersensitivity—Doxorubicin—bone cancer	0.00169	0.00169	CcSEcCtD
Dicyclomine—Vomiting—Methotrexate—bone cancer	0.00169	0.00169	CcSEcCtD
Dicyclomine—Rash—Methotrexate—bone cancer	0.00167	0.00167	CcSEcCtD
Dicyclomine—Dermatitis—Methotrexate—bone cancer	0.00167	0.00167	CcSEcCtD
Dicyclomine—Headache—Methotrexate—bone cancer	0.00166	0.00166	CcSEcCtD
Dicyclomine—Asthenia—Doxorubicin—bone cancer	0.00165	0.00165	CcSEcCtD
Dicyclomine—Dizziness—Epirubicin—bone cancer	0.00164	0.00164	CcSEcCtD
Dicyclomine—Pruritus—Doxorubicin—bone cancer	0.00163	0.00163	CcSEcCtD
Dicyclomine—Vomiting—Epirubicin—bone cancer	0.00158	0.00158	CcSEcCtD
Dicyclomine—Nausea—Methotrexate—bone cancer	0.00158	0.00158	CcSEcCtD
Dicyclomine—Rash—Epirubicin—bone cancer	0.00157	0.00157	CcSEcCtD
Dicyclomine—Dermatitis—Epirubicin—bone cancer	0.00156	0.00156	CcSEcCtD
Dicyclomine—Headache—Epirubicin—bone cancer	0.00156	0.00156	CcSEcCtD
Dicyclomine—Dizziness—Doxorubicin—bone cancer	0.00152	0.00152	CcSEcCtD
Dicyclomine—Nausea—Epirubicin—bone cancer	0.00148	0.00148	CcSEcCtD
Dicyclomine—Vomiting—Doxorubicin—bone cancer	0.00146	0.00146	CcSEcCtD
Dicyclomine—Rash—Doxorubicin—bone cancer	0.00145	0.00145	CcSEcCtD
Dicyclomine—Dermatitis—Doxorubicin—bone cancer	0.00145	0.00145	CcSEcCtD
Dicyclomine—Headache—Doxorubicin—bone cancer	0.00144	0.00144	CcSEcCtD
Dicyclomine—Nausea—Doxorubicin—bone cancer	0.00136	0.00136	CcSEcCtD
